Moreover, it turned out that TRAIL acted independently of p53, which suggested that chemotherapy-resistant tumors caused by inactivating mutations of this tumor suppressor were still sensitive to TRAIL-based therapies [11, 20, 21]. The gene discussed is TNFSF10; the disease is neoplasm.